Раково-тестикуларные антигены как потенциальные мишени для вакцинотерапии опухолей

И. Н. Михайлова, Дмитрий Анатольевич Ковалевский, Бибилашвили Роберт Шалвович · Российский биотерапевтический журнал · 2010

Cancer/Testis (CT) genes are known to be express in germ line cells. Recently, it was shown that these genes are activated in a wide range of cancer types and are immunogenic in cancer patients. These peculiar features of cancer/testis genes could be useful as targets for immunotherapy and also as biomarkers of diagnosis cancer. Many pathophysiologic studies suggest that a blood-testis barrier exists in the testis. Because spermatogenesis begins at puberty, new cell-surface antigens are expressed when the immune system has refined the ability to distinguish self from nonself. So, sperms in the testis do not stimulate immune responses. Based on these observations testis was considered as an immune-privileged site. Testis-specific genes, if expressed in cancers could be immunogenic. For this reason cancer-testis antigens are promising candidates for cancer immunotherapy and have become a major focus for the development of vaccine-based clinical trials in recent years. In addition, these antigens can also be used as biomarkers for early detection of cancers.

Cited by 0 works.

Authors